Thalidomide Therapy for Inflammatory Dermatoses
1984; Wiley; Volume: 23; Issue: 9 Linguagem: Inglês
10.1111/j.1365-4362.1984.tb05696.x
ISSN1365-4632
Autores Tópico(s)Chronic Lymphocytic Leukemia Research
ResumoInternational Journal of DermatologyVolume 23, Issue 9 p. 598-602 Thalidomide Therapy for Inflammatory Dermatoses Edouard Grosshans M. D., Corresponding Author Edouard Grosshans M. D. department of dermatology, Faculty of Medicine, Louis Pasteur University Strasbourg, FranceAddress for reprints: Edouard Grosshans, M.D., Clinique Dermatologique, 1 Place de I'Hibpital, 67091 Strasbourg Cedex, France.Search for more papers by this authorGeneviève Illy M. D., Geneviève Illy M. D. department of dermatology, Faculty of Medicine, Louis Pasteur University Strasbourg, FranceSearch for more papers by this author Edouard Grosshans M. D., Corresponding Author Edouard Grosshans M. D. department of dermatology, Faculty of Medicine, Louis Pasteur University Strasbourg, FranceAddress for reprints: Edouard Grosshans, M.D., Clinique Dermatologique, 1 Place de I'Hibpital, 67091 Strasbourg Cedex, France.Search for more papers by this authorGeneviève Illy M. D., Geneviève Illy M. D. department of dermatology, Faculty of Medicine, Louis Pasteur University Strasbourg, FranceSearch for more papers by this author First published: October 1984 https://doi.org/10.1111/j.1365-4362.1984.tb05696.xCitations: 74AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL references 1 Kunz W, Keller H, Mückter H: N-Phthalyl-glutaminsäure-imid. Arzneimittelforsch 6: 426, 1956. 2 Osterloh G, Lagler F: Zur Verträglichkeit von N-Phthalylglutaminsäure-imid. Arzneimittelforsch 10: 985, 1960. 3 Taussig HB: A study of the German oubreak of phocomelia, JAMA 180: 1106, 1962. 4 Burgio GR: The thalidomide disaster briefly revisited. Eur J Pediatr 136: 229, 1981. 5 Sheskin J: Thalidomide in the treatment of lepra reactions. Clin Pharm Therap 6: 303, 1965. 6 Sheskin J: Therapeutische Erfahrungen über den Einfluss des thalidomids bei der Lepra Reaktion. Hautarzt 26: 1, 1975. 7 Londono F: Thalidomide in the treatment of actinic prurigo. Int J Dermatol 12: 326, 1973. 8 Mattos O: Prurigo nodular de Hyde tratado com talidomida. Bol Div Nac Lepra 32: 71, 1973. 9 Barba-Rubio J, Franco-Gonzalez F: Lupus eritematoso discoide Y talidomida. Dermatologia Rev Mex 19: 131, 1975. 10 Mascaro JM, Lecha M, Torras H: Thalidomide in the treatment of recurrent necrotic and gaint mucocutaneous aphtae and aphthosis. Arch Dermatol 115: 636, 1979. 11 Londono F: Thalidomide for polymorphous light-like eruptions in American Indians. In: Recent Advances in Dermatopharmacology. Edited by P Frost, EC Gomez, N Zaias. New York , Spectrum Publishing, 1978, pp 149– 160. 12 Flores O: Prurigo solar de altiplanicie. Dermatologia Rev Mex 19: 26, 1975. 13 Saul A, Flores O, Novales J: Polymorphous light eruption: Treatment with thalidomide. Aust J Derm 17: 17, 1976. 14 Corrales Padilla H, Dominguez Soto L, Hojyo Tomoka MT, et al: Erupcion polymorfa luminica: Algunos aspectos de interes. Med Cutan Iber Lat Am 7: 81, 1979. 15 Calnan CD, Meara RH: Actinic prurigo (Hutchinson's summer prurigo). Clin Exp Dermatol 2: 365, 1977. 16 Lovell CR, Hawk JLM, Calnan CD, et al: Thalidomide in actinic prurigo. Br J Dermatol 108: 467, 1983. 17 Sheskin J: Zur Therapie der Prurigo nodularis Hyde mit Thalidomid. Hautarzt 26: 215, 1975. 18 Van Den Broek H: Treatment of prurigo nodularis with thalidomide, Arch Dermatol 116: 571, 1980. 19 Nikolowski W: Pruritus und Prurigo. Hautarzt 31: 565, 1980 (cited by Greither). 20 Adame G, Rodriguez G, Leon G: Prurigo Nodular de Hyde: Reporte de dos casos. Dermatologia Rev Mex. 21 Winkelmann RK, Connolly SM, Doyle JA, et al: The thalidomide treatment of prurigo nodularis. Arch Dermatol (submitted). 22 Samsoen M, Grosshans E, Basset A: La thalidomide dans le traitement du lupus érythémateux chronique. Ann Dermatol Venereol 107: 515, 1980. 23 Levi L, Saggiorato F, Crippa D: Attività e meccanismo d'azione della talidomide in 18 pazienti affetti da lupus eritematoso discoide fisso. Giorn Ital Derm Vener 115: 471, 1980. 24 Knop J, Happle R, Vakilzadeh F, et al: Treatment of lupus erythematosus profondus with thalidomide. Arch Dermatol Res 270: 229, 1981. 25 Knop J, Happle R, Bonsmann G, et al: Treatment of chronic discoid lupus erythematosus with thalidomide. Arch Dermatol Res 271: 165, 1981. 26 Hasper MF, Klokke AH: Thalidomide in the treatment of chronic discoid lupus erythematosus. Acta Derm Venereol 62: 321, 1982. 27 Scolari F, Harms M, Gilardi S: La thalidomide dans le traitement du lupus érythémateux chronique. Dermatologica 165: 355, 1982. 28 Naafs B, Bakkers EJM, Flinterman J, et al: Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermotol 107: 83, 1982. 29 Torras H, Lecha M, Mascaro JM: La talidomida en el tratamento de las aftosis y enfermedad de Behçet: Experencia de cuatro anos. Med Cutan Iber Lal Am 10: 103, 1982. 30 Saylan T, Saltik I: Thalidomide in the treatment of Behçet's syndrome. Arch Dermatol 118: 536, 1982. 31 Hamza M, Chaffai M, Ben Ayed H: Le traitement de la maladie de Behçet par la thalidomide. Nouv Presse Med 11: 1080, 1982. 32 Küffer R, Puissant A: Bericht über die 64. Jahresversammlung der Schweizer Gesellschaft für Dermatologie. Hautarzt 34: 306, 1983 (cited by Paschoud). 33 Pinol-Aguade J, Lecha M, Castells Rodellas A, et al: Osservazioni di qualche fotodermatosi con reazione persistente alla luce. Giorne Min Derm 109: 129, 1975. 34 Moulin G, Bonnet F, Barrut D, et al: Traitement de la maladie de Jessner et Kanof par la thalidomide. Ann Dermatol Venereol 110: 611, 1983. 35 Venencie PY, Saurat JH: Pyoderma gangrenosum chez un enfant: Traitement par la thalidomide. Ann Pédiatr 29: 67, 1982. 36 Waters MFR, Laing ABG, Ambikapathy A, et al: Treatment of ulcerative colitis with thalidomide. Br Med J 1: 792, 1979. 37 Eravelly J, Waters MFR: Thalidomide in Weber-Christian disease. Lancet i: 251, 1977. 38 Pfannenstiel H: Leishmaniasis cutanea recidivans. Hautarzt 30: 221, 1979. 39 Bahmer FA, Zaun H, Luszpinski P: Thalidomide treatment of recurrent erythema multiforme. Acta Derm Venereol 62: 449, 1982. 40 Barriere H: Sarcoides cutanéés. Traitement par la thalidomide. Presse Méd 12: 963, 1983. 41 Lewis HBM, Albert-Recht F, Walker W: Cold haemo-agglutination disease treated by thalidomide. Br Soc Haematol 15: 322, 1968. 42 Hunziker T, Krebs A: Thalidomid in der Dermatologie. Hautarzt 34: 66, 1983. 43 Barnhill RL, McDougall AC: Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol 7: 317, 1982. 44 Dukor P, Dietrich FM: Immunosuppression by thalidomide Lancet i: 569, 1967. 45 Coleman MB, Morales MJ, Botero Gl, et al: The effect of thalidomide on a quantitative precipitin reaction in vitro. Int J Leprosy 42: 368, 1974. 46 Goihman-Yahr M, Convit J, Rodriguez-Ochoa G, et al: Significance of neutrophil activation in reactional lepromatous leprosy: Effects of thalidomide in vivo and in vitro. Activation in adjuvant disease. Int Arch Allergy Appl Immun 57: 317, 1979. 47 Faure M, Thivolet J, Gaucherand M: Inhibition of PMN-leukocytes chemotaxis by thalidomide. Arch Dermatol Res 269: 275, 1980. 48 Shannon EJ, Miranda RO, Morales MJ, et al: Inhibition of de novo lgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol 13: 553, 1981. 49 Hendler SS, McCarty MF: Thalidomide for autoimmune disease. Med Hypotheses 10: 437, 1983. 50 Miyachi Y, Ozaki M, Uchida K, et al: Effects of thalidomide on the generation of oxygen intermediates by zymosan-stimulated normal polymorphonuclear leukocytes. Arch Dermatol Res 274: 363, 1982. 51 Fickentscher K, Haltmann U, Köhler F: Synthese und teratogene Aktivität von thalidomid-analogen 1,3-Indandionen. Arch Pharmacol 313: 481, 1980. 52 Kocher-Becker U, Kocher W, Ockenfels H: Teratogenic activity of a hydrolytic thalidomide metabolite in mice. Naturwissenschaften 69: 191, 1982. 53 Helm FC, Frankus E, Friderichs E, et al: Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide. Arzneimittelforsch 31: 941, 1981. 54 Sheskin J: Study with nine thalidomide derivatives in the lepra reaction. Int J Dermatol 17: 82, 1978. 55 Sheskin J, Mückter H, Frankus E: Supidimid, ein nicht teratogenes thalidomidanalog zur Behandlung der Lepreaktion. Hautarzt 34: 168, 1983. 56 Lutwak-Mann C, Schmid K, Keberle H: Thalidomide in rabbit semen. Nature 214: 1018, 1967. 57 Reyes Flores O: Tratamiento de la lepra. Dermatol Venezolana 17: 1, 1979. 58 Mellin GW, Katzenstein M: The saga of thalidomide: Neuropathy to embryopathy with case reports of congenital anomalies. N Engl J Med 267: 1184, 1962. 59 Fullerton PM, O'Sullivan DJ: Thalidomid neuropathy: A clinical, electrophysiological and histological follow-up study. J Neurol Neurosurg Psychiat 31: 543, 1968. 60 Ludolph A, Matz DR: Elektrophysiologische Veränderungen bel Thalidomidneuropathie unter Behandlung des Lupus erythematodes discoides. Z EEG-EMG 13: 167, 1982. 61 Schröder JM, Gibbels E: Marklose Nervenfasern im Senium und im Spätstadium der Thalidomid-Polyneuropathie: Quantitative-elektronenmikroskopische Untersuchungen. Acta Neuropath 39: 217, 1977. Citing Literature Volume23, Issue9October 1984Pages 598-602 ReferencesRelatedInformation
Referência(s)